Elevance Health (ELV) Could Be 7% Undervalued On Reaffirmed 2026 Guidance
Elevance Health (ELV) used its Wells Fargo healthcare conference appearance on 10 September 2026 to reaffirm full-year earnings and benefit expense ratio guidance, giving investors fresh insight into management’s expectations for the rest of the year.
Elevance Health’s reaffirmed guidance comes after a steady run in the stock, with a 30 day share price return of 4.6% and an 18.2% share price return year to date. The 1 year total shareholder return of 37% points to momentum that recent conference comments may help sustain.
Expand your watchlist beyond Elevance Health by scanning a hand picked list of solid balance sheet and fundamentals (23 results) that, like ELV, puts financial resilience and cost control at the center of its story.
After a strong run in Elevance Health and fresh guidance from management, the gap between the current US$418.72 share price, analyst targets, and longer term intrinsic estimates now matters more than ever. Where does fair value actually land?
Most Popular Elevance Health Narrative: 6.8% Undervalued
On this view, Elevance Health’s $449.10 fair value estimate sits modestly above the last close at $418.72, so the gap hinges on what drives future margins and earnings power.
Elevance's ongoing expansion of value-based care arrangements, particularly within behavioral health and oncology, and the scaling of risk-based contracts through its Carelon division, position the company to benefit from increased cost predictability, better care coordination, and reduced volatility in medical cost ratios, supporting future margin expansion.
Want to see what is baked into that margin story? The narrative leans on a specific earnings path, disciplined capital returns, and a future multiple that tightens the valuation maths.
Result: Fair Value of $449.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, elevated Medicaid utilization and slower rate recovery, along with integration risks in Carelon acquisitions, could challenge Elevance Health’s margin recovery story if these pressures persist.
Find out about the key risks to this Elevance Health narrative.
Next Steps
Positive and cautious threads both run through the Elevance Health story, so move quickly, pull up the full data, and pressure test the optimism by reviewing the 4 key rewards.
Looking for more investment ideas beyond Elevance Health?
If you stop at Elevance Health, you risk missing other compelling setups. Use the Simply Wall St Screener to hunt for ideas that fit your playbook.
- Target resilient balance sheets by reviewing a focused list of solid balance sheet and fundamentals (23 results) that filters for companies prioritising financial strength and disciplined fundamentals.
- Chase potential mispricing and scan a curated 32 high quality undervalued stocks that highlights businesses screened for quality metrics at compressed valuations.
- Strengthen your income stream and study a hand picked 6 dividend fortresses built around companies offering higher yields with supporting fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com